Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AstraZeneca SARS-CoV-2 vaccination and coagulation activation biomarkers study
NL-OMON51038Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoints: Presence of thrombin-antithrombin complex above detection level in peripheral blood, Presence of plasma kallikrein:C1 inhibitor complex above detection level in peripheral blood and 5 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51038.